Trisol Medical Announces Positive Results from U.S. Early Feasibility Study of Its Transcatheter Tricuspid Valve Replacement System
Results demonstrate a favorable safety profile and functional improvements in patients with…
Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea
Daridorexant is a dual orexin receptor antagonist being developed by Nxera for…
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
• Patient 1 of Cohort 1 has now completed the 24-month follow-up…
S&P Upgrades IIFL Finance’s Outlook to ‘Positive’ On Recovering Market Share in Gold Loans; ‘B+/B’ Ratings Affirmed
MUMBAI, India, Dec. 18, 2025 /PRNewswire/ -- Credit Rating agency Standard and…
Igyxos Biotherapeutics Announces Positive Results from Phase 1 Trial of IGX12, its First-in-Class Monoclonal Antibody for the Treatment of Male and Female Infertility
December 10, 2025 04:00 ET | Source: Igyxos TOURS, France, Dec. 10,…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET | Source: Cerevance, Inc. Phase 2 results…
